Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company’s strategic focus areas for 2025 at the 43rd Annual J.P. Morgan Healthcare ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) saw its stock price soar by an impressive 33.87%, reaching $7.43 during Monday’s premarket trading session. The surge came on the heels of the company’s ...

Tennessee has long had one of the highest maternal death rates in the nation, but newly released data shows the risks of ...

The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum depression.

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on GHRS stock, giving a Buy rating yesterday.Stay Ahead of the ...

Newmi Care, founded by Aditi Mittal and Sanchit Agarwal in 2022, is a full-stack platform that addresses various aspects of ...

There's a lot to cover during a postpartum checkup. Here are some questions you'll want to ask and what you can expect.

Telehealth company Talkiatry has partnered with Biogen to expand its support service for women who develop postpartum depression (PPD ... to delayed diagnosis and treatment.

the first pill for severe postpartum depression. A two-week course costs nearly $16,000, and insurance coverage is inconsistent. Dr. Monk says progress has been made when it comes to treatment ...